Ben Dallah S K, Lenghi M
Salaheddin University Hospital, Tripoli, Libya.
J Int Med Res. 1994 Jul-Aug;22(4):218-24. doi: 10.1177/030006059402200403.
Nabumetone is the first of a new alkalone class of non-steroidal anti-inflammatory drugs with a lower propensity for gastric irritation than either aspirin or indomethacin. The efficacy and tolerability of nabumetone was studied in 75 patients suffering from acute or chronic osteoarthritis of the knee joint. The efficacy of treatment with 1 g nabumetone daily for 8 weeks was very good. Both swelling and effusion were completely resolved in all patients at the end of 4 weeks. Improvements in functional capacity, restriction of movement and pain were seen in 43-73% of patients at week 2 and in 72-92% at week 4. The overall response was subjectively assessed at week 8 as excellent or good in 83% of cases both by the patients and by the investigators. Nabumetone was particularly well tolerated; no adverse events or changes in laboratory values were reported.
萘丁美酮是新型的一类非甾体抗炎药中的首个药物，与阿司匹林或吲哚美辛相比，其引起胃刺激的倾向较低。对75例膝关节急性或慢性骨关节炎患者研究了萘丁美酮的疗效和耐受性。每天服用1 g萘丁美酮，治疗8周，疗效非常好。4周结束时，所有患者的肿胀和积液均完全消退。在第2周，43% - 73%的患者功能能力、活动受限和疼痛有所改善；在第4周，72% - 92%的患者有改善。在第8周主观评估总体反应，患者和研究者均认为83%的病例为优或良。萘丁美酮耐受性特别好；未报告有不良事件或实验室值变化。
